TIMOGLOBULINA 5 mg/ml
Sponsors
Hospital Universitario La Paz, Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca, Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
Conditions
Chronic Kidney DiseaseKidney TransplantKidney transplantationadvanced chronic renal insufficiency
Phase 4
MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE
EFFICACY OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK
BASED ON SELECTIVE BIOMARKERS (HLA
EPLETH DISPARITY AND IFN-γ ELISPOT) TO OPTIMIZE IMMUNOSUPPRESSIVE
TREATMENT IN LIVING DONOR KIDNEY TRANSPLANT PATIENTS (BIOIMMUN)
Not yet recruitingCTIS2025-520884-42-00
Target: 164Updated: 2025-01-30
Use of tacrolimus and MTOR inhibitors with anticipatory therapy vs. tacrolimus and mycophenolic acid with universal prophylaxis in renal recipients at high risk of post-transplant cytomegalovirus. Phase IV clinical trial (TIMTOR STUDY).
Not yet recruitingCTIS2025-520854-12-00
Target: 30Updated: 2026-01-20
Phase IV, randomized, open-label study comparing the use of Grafalon® versus Thymoglobulin® in non-sensitized patients who have received a kidney transplant at high risk of delayed graft function
Not yet recruitingCTIS2026-526938-23-00
Target: 104Updated: 2026-10-19